Search your couch cushions… search through your coat pockets, because every Monday my algorithm finds Breakout Blockbusters trading for pocket change that could have you jumping for joy on top of an enormous pile of cash…

I’m talking about gains like 89.5% on Nuburu Inc… and a 149% on MSS… and even a rare 536% on Rebel Holdings all within a single day!

Just to name a few…

And it happens like clockwork every Monday on a small group of stocks that all trade for less than $5. 

So while everyone else is buying and holding overpriced, overhyped stocks like META, NVDA or AMZN for potential one-digit or two annual returns…

You can trade these stocks with your pocket change and make more money in a single day.

So take a few moments to click here and watch my video dossier, because we already have a trade lined up for Monday…

And if I’m right, this one could move 100% quickly.

So hurry up and get access to my Monday Algo trades on my website here.

>>Reveal Ticker<<

Look forward to seeing you on Monday

---

Exclusive Content from MarketBeat

This ETF Is Proof That the Healthcare Rebound Is Real

Author: Jordan Chussler. Originally Published: 1/11/2026. 

Key Points

• After years of trailing the S&P 500, health care has rebounded, leading all other sectors with a 19% gain over the past six months.
• The bullish case for that rally to continue involves America’s GLP-1 drug obsession and incredibly low health care stock valuations.  
• The Vanguard Health Care ETF provides broad exposure and is off to a strong start in 2026.

Well-publicized losses at companies such as UnitedHealth Group (NYSE: UNH), Elevance Health (NYSE: ELV), and Wegovy and Ozempic maker Novo Nordisk (NYSE: NVO) left the healthcare sector unable to outperform the broader market in 2025.

In the three-year period from 2022 through 2024, the sector posted modest results: a 2.6% gain in 2024, a 2.1% gain in 2023 and a 2.0% decline in 2022.

Wall Street ‘Sleeper Stock’ Could Become #1 Stock of 2026 (Ad)

Wall Street veteran reveals #1 investment trend of 2026 (not AI)

Will you potentially make money or lose money in the U.S. stock market in 2026? According to the 50-year Wall Street legend who invented one of Wall Street’s most popular buying and selling indicators – the answer has nothing to do with AI, quantum computing, or cryptos. Instead, it all comes down to the #1 stock he recommends you BUY now…And the #1 stock he recommends you SELL now.

But healthcare stocks now appear to have turned a corner. Over the past six months, the sector—whose demand tends to be inelastic—has led all 11 S&P 500 sectors with a nearly 19% gain.

Investment professionals say the momentum that began in mid-2025 is likely to carry into the new year.

For shareholders of the Vanguard Health Care ETF (NYSEARCA: VHT), that shift is already showing up in results.

2 Major Catalysts for the Health Care Sector

Two key tailwinds should help healthcare stocks sustain the rally. One—the mass adoption of weight-loss drugs—helped spark the sector’s bullish reversal in mid-2025. The other—relatively low valuations—could continue to attract inflows as investors rotate out of higher‑volatility positions.

America’s Weight-Loss Treatment Craze

Weight-loss treatments, including GLP-1 agonists and semaglutide drugs such as Novo Nordisk’s Ozempic and Wegovy, are becoming more widely adopted.

Pharmaceutical companies are also shifting from injectables to pill formulations, while firms like Pfizer (NYSE: PFE) are doubling down on investments in the weight-loss market.

Commenting on the drugs’ popularity, Catherine Brown, vice president of clinical services at digital health firm Welldo, told Reuters: “We’re imagining these medications may become so common that everybody’s got a GLP-1 app … right there on your phone next to your bank account.”

Industry consultancy Grand View Research forecasts the GLP-1 market could grow at a compound annual growth rate of 18.54% from 2024 to 2030, increasing global market value from $13.84 billion to $48.84 billion.

Low Healthcare Stock Valuations Are Attracting Inflows

After President Trump’s tariff announcements in April 2025—which affected imported pharmaceuticals—many healthcare stocks traded at relatively low valuations compared with persistently high multiples in technology and communication services.

For example, Pfizer has a trailing 12-month (TTM) price-to-earnings (P/E) ratio of 14.7, while benefits provider Elevance and Johnson & Johnson (NYSE: JNJ) trade at P/E multiples of about 15.32 and 19.86, respectively.

By contrast, some tech names still command sky-high multiples: Palantir (NASDAQ: PLTR) and Tesla (NASDAQ: TSLA) reported TTM P/E ratios near 421.11 and 290.53, respectively.

Those valuation gaps have drawn the attention of value-minded investors, leading to renewed interest in healthcare stocks at the end of 2025 and into 2026.

In November 2025, Mizuho healthcare equity strategist Jared Holz told Barron’s, “When you see money come out of a space, especially one that’s filled with trillion-dollar [tech] companies, it really doesn’t take much to get some of the underperforming sectors a little juice.”

Vanguard’s VHT: A Basket of Undervalued Stocks

The Vanguard Health Care ETF is up 2.30% so far this year after gaining more than 18% over the past six months. Much of that performance was driven by rebounds and strong year-end showings from the fund’s top holdings.

VHT’s largest positions include Eli Lilly (NYSE: LLY), AbbVie (NYSE: ABBV), Johnson & Johnson, UnitedHealth and Merck (NYSE: MRK).

The ETF also holds allocations to Pfizer, CVS Health (NYSE: CVS)—which acquired Aetna in 2018—and the nation’s largest hospital chain, HCA Healthcare (NYSE: HCA).

VHT carries a low expense ratio of 0.09% and pays a dividend that currently yields 1.58%, or about $4.64 per share annually.

What Wall Street Thinks About VHT

Based on analysts’ ratings of 23 companies in VHT’s portfolio (covering roughly 64.3% of the fund), the ETF receives a Moderate Buy rating.

Perhaps the clearest sign of Wall Street’s growing enthusiasm is VHT’s current short interest, just 0.33% of the float—fewer than 195,000 shares out of about 60.17 million outstanding. That represents nearly a 37% decrease in short interest since the prior reporting period.

Thank you for subscribing to The Early Bird, MarketBeat’s 7:00 AMnewsletter that covers stories that will impact the stock market each day.

This email content is a paid advertisement from StocksToTrade, a third-party advertiser of The Early Bird and MarketBeat. 


Results are not typical and will vary from person to person. Making money trading stocks takes time, timing, proper execution, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk.


If you have questions about your subscription, feel free to email our South Dakota based support team at contact@marketbeat.com.

If you no longer wish to receive email from The Early Bird, you can unsubscribe.

© 2006-2026 MarketBeat Media, LLC. All rights reserved.
345 N Reid Place #620, Sioux Falls, South Dakota 57103. United States..

Today’s Bonus Content: No AI Bots. Just Real Signals. (Click to Opt-In)